╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Any condition(s) that, in the opinion of the       │ 13. Any condition(s) that, in the opinion of the   │
│ investigator, might interfere with adherence to    │ investigator, might interfere with adherence to    │
│ study requirements or evaluation of the study      │ study requirements or evaluation of the study      │
│ objectives                                         │ objectives                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HIV-negative as determined by a HIV rapid test at  │ 5. HIV-negative as determined by a HIV rapid test  │
│ time of enrollment                                 │ at time of enrollment                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Asymptomatic for genital infections at the time of │ 9. Asymptomatic for genital infections at the time │
│ enrollment                                         │ of enrollment                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Healthy and self-reported sexually active          │ 4. Healthy and self-reported sexually active       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previously participated in any HIV vaccine study   │ 4. Previously participated in any HIV vaccine      │
│                                                    │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Willing to refrain from participation in any other │ 12. Willing to refrain from participation in any   │
│ research study for the duration of this study      │ other research study for the duration of this      │
│                                                    │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must be FEMALE                                     │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Upon pelvic/speculum examination and colposcopy at │ 8. Upon pelvic/speculum examination and colposcopy │
│ the time of enrollment, the cervix and vagina      │ at the time of enrollment, the cervix and vagina   │
│ appear normal as determined by the investigator    │ appear normal as determined by the investigator    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any serious acute, chronic or progressive disease  │ 12. Any serious acute, chronic or progressive      │
│                                                    │ disease                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women 18 to 40 years of age inclusive who can give │ 1. Women 18 to 40 years of age inclusive who can   │
│ written informed consent                           │ give written informed consent                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ On a stable form of contraception and willing to   │ 6. On a stable form of contraception and willing   │
│ continue on this stable method of contraception    │ to continue on this stable method of               │
│                                                    │ contraception, OR, Have undergone surgical         │
│                                                    │ sterilisation at least 3 months prior to           │
│                                                    │ enrollment                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pap smear result at screening that requires        │ 8. Pap smear result at screening that requires     │
│ cryotherapy, biopsy, treatment (other than for     │ cryotherapy, biopsy, treatment (other than for     │
│ infection), or further evaluation                  │ infection), or further evaluation                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently pregnant or last pregnancy outcome       │ 1. Currently pregnant or last pregnancy outcome    │
│ within 3 months prior to enrolment                 │ within 3 months prior to enrolment                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of abnormal physical finding on the       │ 6. Presence of abnormal physical finding on the    │
│ vulva, vaginal walls or cervix during              │ vulva, vaginal walls or cervix during              │
│ pelvic/speculum examination and/or colposcopy      │ pelvic/speculum examination and/or colposcopy      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Willing to answer acceptability and adherence      │ 11. Willing to answer acceptability and adherence  │
│ questionnaires throughout the study                │ questionnaires throughout the study                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have maximum age of 40 Years                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have undergone surgical sterilisation at least 3   │ 6. On a stable form of contraception and willing   │
│ months prior to enrollment                         │ to continue on this stable method of               │
│                                                    │ contraception, OR, Have undergone surgical         │
│                                                    │ sterilisation at least 3 months prior to           │
│                                                    │ enrollment                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently breast-feeding                           │ 2. Currently breast-feeding                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participated in any other research study within 60 │ 3. Participated in any other research study within │
│ days prior to screening                            │ 60 days prior to screening                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Willing to provide adequate locator information    │ 13. Willing to provide adequate locator            │
│ for study retention purposes and be reachable per  │ information for study retention purposes and be    │
│ local standard procedures                          │ reachable per local standard procedures            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of significant urogenital or uterine       │ 7. History of significant urogenital or uterine    │
│ prolapse, undiagnosed vaginal bleeding, urethral   │ prolapse, undiagnosed vaginal bleeding, urethral   │
│ obstruction                                        │ obstruction                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unexplained, undiagnosed abnormal bleeding per     │ 10. Unexplained, undiagnosed abnormal bleeding per │
│ vagina, bleeding per vagina during or following    │ vagina, bleeding per vagina during or following    │
│ vaginal intercourse, or gynaecologic surgery       │ vaginal intercourse, or gynaecologic surgery       │
│ within 90 days prior to enrollment                 │ within 90 days prior to enrollment                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any Grade 2, 3 or 4 baseline haematology,          │ 9. Any Grade 2, 3 or 4 baseline haematology,       │
│ chemistry or urinalysis laboratory abnormality     │ chemistry or urinalysis laboratory abnormality     │
│ according to the DAIDS Table for Grading Adverse   │ according to the DAIDS Table for Grading Adverse   │
│ Experiences                                        │ Experiences                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Willing to refrain from use of vaginal products or │ 10. Willing to refrain from use of vaginal         │
│ objects within 14 days prior to enrollment and for │ products or objects within 14 days prior to        │
│ the duration of the study                          │ enrollment and for the duration of the study       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Available for all visits and consent to follow all │ 2. Available for all visits and consent to follow  │
│ procedures scheduled for the study                 │ all procedures scheduled for the study             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the absence of the use of exogenous hormone(s), │ 7. In the absence of the use of exogenous          │
│ have a self-reported regular menstrual cycle       │ hormone(s), have a self-reported regular menstrual │
│ defined as having a minimum of 21 days and a       │ cycle defined as having a minimum of 21 days and a │
│ maximum of 36 days between menses                  │ maximum of 36 days between menses                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated urogenital infections (either            │ 5. Untreated urogenital infections (either         │
│ symptomatic or asymptomatic) within 2 weeks prior  │ symptomatic or asymptomatic) within 2 weeks prior  │
│ to enrollment                                      │ to enrollment                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any history of anaphylaxis or severe allergy       │ 11. Any history of anaphylaxis or severe allergy   │
│ resulting in angioedema; or a history of           │ resulting in angioedema; or a history of           │
│ sensitivity/allergy to latex                       │ sensitivity/allergy to latex                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Agree to daily application of gel and monitoring   │ 3. Agree to daily application of gel and           │
│ as per Daily Monitored Adherence (DMA) method      │ monitoring as per Daily Monitored Adherence (DMA)  │
│                                                    │ method                                             │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛